About Us

About Us

LogicBio, launched in 2016, is building on the pioneering work of gene therapy leaders from Stanford University.

Our technology, GeneRide™, enables highly specific genome editing and integration of the therapeutic transgene, utilizing the body's own native processes to drive durable expression.

We are initially targeting a wide range of diseases not addressable today, including early-onset conditions in young patients.

We are a world-class global team, headquartered in Cambridge, Massachusetts, working to deliver the next wave of innovation in genetic medicine.

Leadership team

Fred Chereau

Fred Chereau

President and Chief Executive Officer

Frederic Chereau has more than 25 years of experience leading groundbreaking biotherapeutics companies, and successfully guiding products from proof-of-concept and clinical trial through commercialization. Prior to joining LogicBio, Fred held various general management and biotech executive positions at Genzyme, Pervasis Therapeutics, Shire and aTyr Pharma. He holds an undergraduate degree in physics from Paris University, a Master’s degree from ESC La Rochelle and an MBA from INSEAD.

Matthias Jaffe

Matthias Jaffé

Chief Financial Officer

Matthias Jaffé is an accomplished leader in early life science financial and strategic management. Over the last 15 years, Matthias has served as chief financial officer for Constellation Pharmaceuticals, Zafgen, Pervasis Therapeutics and Alantos Pharmaceuticals. He holds an M.Sc. from MIT and an MBA from INSEAD, and is an avid paragliding pilot.

Tom Wilton

Tom Wilton

Chief Business Officer

Tom Wilton has an extensive background in business development, corporate strategy and commercial operations across the pharma, academic and biotech sectors. Previously, Tom served as chief business officer for the University of Pennsylvania’s Gene Therapy Program, and played an instrumental role in the establishment of GSK’s Rare Diseases Business Unit. He holds graduate degrees from the University of Leeds and Brunel University.

Nelson Chau, PhD

Nelson Chau, Ph.D.

Vice President, Discovery Biology and Translational Research

Nelson Chau is a seasoned biotech veteran with deep experience in drug discovery and translational research. Prior to joining LogicBio, he served as vice president of drug discovery at Translate Bio and director of research at Regulus Therapeutics where he contributed to the discovery and preclinical development of multiple RNA-based therapeutics. Nelson earned his Ph.D. from the Johns Hopkins University School of Medicine and was a Damon Runyon Fellow.

Kelly Blackburn

Kelly Blackburn

Clinical and Regulatory Strategist

A specialist in rare disease and deep clinical drug development, Kelly Blackburn has built a career guiding transformative drugs from first-in-human trials to launch. She began her career at Bayer and Genetics Institute, and later went on to drive clinical development programs at Millennium Pharmaceuticals, Vertex and aTyr Pharma. Kelly holds a B.S. in biochemistry from the University of New Hampshire, an M.H.A. from Quinnipiac University and an M.Ed. from Cambridge College. Away from the office, Kelly devotes herself to non-profit work.

Kyle Chiang, PhD

Kyle Chiang, Ph.D.

Vice President, Portfolio Management and Operations

Kyle Chiang has more than 10 years of rare disease drug development experience as a key member of discovery and clinical science teams. Most recently, he served as program executive of ATYR1940 at aTyr Pharma, where he led the program through early clinical development for patients with facioscapulohumeral muscular dystrophy. Kyle received his Ph.D. in macromolecular cellular structure and chemistry from the Scripps Research Institute.

Scientific Founders

  • Mark Kay, M.D., Ph.D.

    Mark Kay is the Dennis Farrey Family Professor in Pediatrics, and a professor of genetics at Stanford University School of Medicine, where he heads the division of human gene therapy. It is out of his lab – the storied Kay Lab at Stanford Medicine – where he and his co-founders developed the core technologies that were to become LogicBio. Dr. Kay is a leading researcher and luminary in the fields of gene therapy and AAV biology, including the identification of new AAV capsids. A founder of the American Society of Gene and Cell Therapy, Dr. Kay served as the society’s president from 2005 to 2006, and was the recipient of its ‘Outstanding Investigator’ Award in 2013. He is currently the editor of Human Gene Therapy and serves on the editorial boards of other peer-reviewed publications.

  • Adi Barzel, Ph.D.

    Adi Barzel is President-elect of the Israeli Society of Gene and Cell Therapy and a senior lecturer in the Department of Biochemistry at Tel Aviv University. Dr. Barzel is a renowned expert in homologous recombination and gene targeting. He is a Summa cum Laude graduate of the Adi Lautman interdisciplinary program for outstanding students, and has earned his Ph.D. in genetics from the laboratory of Professor Martin Kupiec at Tel Aviv University. Previously, Dr. Barzel was a company commander in an armor brigade and in the officer’s academy of the Israeli Defense Forces. He has co-authored scientific papers in high-impact journals describing the GeneRide™ technology and its applications.

  • Leszek Lisowski, Ph.D., MBA

    Leszek Lisowski is an associate professor and group leader at University of Sydney, Children’s Medical Research Institute (CMRI)/University of Sydney in Australia and the Military Institute of Hygiene and Epidemiology (MIHE) in Poland. Dr. Lisowski is a recognized expert in viral gene therapy, vectorology and genotoxicity and has developed novel lentiviral and AAV vectors that are in clinical evaluation in numerous academic and industry sponsored clinical studies. He has also established a Vector and Genome Engineering Facility at CMRI that specialises in development of AAV vectors and genome engineering technologies. Dr. Lisowski earned his Ph.D. from Cornell University and MBA from University of California San Diego.

Board of Directors

  • Leon Chen, Ph.D.

    OrbiMed Advisors, Venture Partner

  • Frederic Chereau, MBA

    President and CEO

  • Erez Chimovits, MBA

    OrbiMed Advisors, Senior Managing Director

  • Sofia Ioannidou, Ph.D.

    Edmond de Rothschild Investment Partners, Investment Director

  • Tomer Kariv, J.D.

    Pontifax, Founder & CEO

  • Mark Kay, M.D., Ph.D.

    LogicBio Co-founder;
    Stanford University, Dennis Farrey Family Professor in Pediatrics & Professor of Genetics

  • Daniel O’Connell, M.D., Ph.D.

    Arix Bioscience, Investment Manager